Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Summary

The primary objectives of this study are to evaluate the safety and tolerability of emerfetamab in adults with relapsed/refractory acute myeloid leukemia (AML) and to estimate the maximum tolerated dose (MTD) and/or a biologically active dose (eg, recommended phase 2 dose \[RP2D\]).

Timeline

Start

2017-09-07

Primary completion

2020-12-28

Completion

2020-12-28

Outcome

Outcome not reported

Stopped: “Priortization of other Programs”

Drugs

Indications